Researchers at the University of Liverpool have conducted a large-scale analysis that sheds light on the critical steps ...

Viral infections are a predominant cause of liver disease around the world, impacting millions with conditions ranging from mild inflammation to severe ...

A new study that has the potential to change the landscape of hepatitis B transmission in Africa. Researchers at the University of Liverpool and Liverpool School of Tropical Medicine conducted ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...

What’s the difference between influenza A and influenza B, and does it matter which you ... “You tend to have one or the other virus predominant at any given time,” said Anice Lowen, a ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

The company had been holding out hopes that the candidate could be another functional cure for the infection—meaning it reduces hepatitis B virus DNA and viral proteins to undetectable levels.